Eisai Co., Ltd. ESALF
32.58 USD 0.00 (+0.00%)
At closeNov 11, 2026, 4:00 PM EST
34.07 Day range 34.07
23.88 52-week range 35.00
- YTD
- +9.59%
- 1 year
- +19.08%
News
seekingalpha.com Eisai Co., Ltd. (ESAIY) Q2 2027 Earnings Call Transcript Eisai Co., Ltd. (ESAIY) Q2 2027 Earnings Call Transcript
seekingalpha.com Eisai Co., Ltd. (ESAIY) Q1 2027 Earnings Call Transcript Eisai Co., Ltd. (ESAIY) Q1 2027 Earnings Call Transcript
reuters.com FDA approves at-home starter dose of Eisai-Biogen Alzheimer's drug The U.S. FDA on Monday approved an at-home starting dose of Eisai's and Biogen's Alzheimer's drug, allowing some patients to begin therapy with injections administered by themselves or a caregiver.
seekingalpha.com Eisai Co., Ltd. (ESAIY) Analyst/Investor Day Transcript Eisai Co., Ltd. (ESAIY) Analyst/Investor Day Transcript
prnewswire.com BioArctic Interim Report for the period January - March 2026 STOCKHOLM, May 20, 2026 /PRNewswire/ -- Strong financial performance with commercial milestone reached Events during the first quarter 2026 Leqembi® Iqlik™ (subcutaneous formulation) was granted…
seekingalpha.com Eisai Co., Ltd. (ESAIY) Q4 2026 Earnings Call Transcript Eisai Co., Ltd. (ESAIY) Q4 2026 Earnings Call Transcript
reuters.com Merck-Eisai's combination cancer therapy fails to meet main goals of late-stage study Merck and Eisai's experimental combination treatments for a type of kidney cancer failed to meet the main goals of a late-stage study, the companies said on Tuesday.
marketwatch.com These Alzheimer's drugs were supposed to revolutionize the way we fight the disease. The reality is more complicated. A scientific report has raised questions about how much Leqimbi and Kisunla — the “breakthrough” Alzheimer's drugs that have hit the market in the last few years — really help slow the disease.
prnewswire.com Eisai to Present the Latest Data on Real-World Treatment with Lecanemab and Supporting a Standardized Framework for Treating Early Alzheimer's Disease at the 78th American Academy of Neurology's Annual Meeting NUTLEY, N.J., April 9, 2026 /PRNewswire/ -- Eisai Inc. announced today the company will present the latest findings on lecanemab (generic name, brand name: LEQEMBI®), Eisai's anti-amyloid beta (Aβ)…
prnewswire.com Eisai and Nuvation Bio Announce Marketing Authorisation Application for Taletrectinib for the Treatment of Advanced ROS1-Positive Non-Small Cell Lung Cancer Validated by the European Medicines Agency The Marketing Authorisation Application (MAA) has been validated and accepted for full approval consideration with a standard review timeline Additional filings are planned for the U.K., Canada and…
prnewswire.com BioArctic Interim Report for the period October - December 2025 STOCKHOLM, Feb. 18, 2026 /PRNewswire/ -- A transformative year with record financial results Events during the fourth quarter 2025 Leqembi® Iqlik™ was launched for weekly maintenance dosing and Eisai…
seekingalpha.com Eisai Co., Ltd. (ESAIY) Q3 2026 Earnings Call Transcript Eisai Co., Ltd. (ESAIY) Q3 2026 Earnings Call Transcript
benzinga.com Medicare Targets 15 High-Profile Drugs In Third Price Negotiation Cycle CMS selects 15 high-cost prescription drugs for Medicare drug price negotiation program, expanding to include Part B drugs.
businesswire.com Nuvation Bio and Eisai Enter into Exclusive Licensing Agreement for Taletrectinib in Europe and Additional Countries Outside U.S., China and Japan NEW YORK & TOKYO--(BUSINESS WIRE)--Nuvation Bio Inc. (NYSE: NUVB, Corporate Headquarters: New York, NY, CEO: David Hung, M.D., “Nuvation Bio”), a global oncology company focused on tackling some of…
businesswire.com EA Pharma, a subsidiary of Eisai, Announces the Initiation of its Phase III Clinical Trial with Evenamide, a Novel Treatment for Schizophrenia, in Japan MILAN & MORRISTOWN, N.J.--(BUSINESS WIRE)---- $NWRN #schizophrenia--Newron's partner EA Pharma Co., Ltd. announces today the initiation of its Phase III clinical trial with evenamide in Japan.
seekingalpha.com Eisai Co., Ltd. (ESAIY) Discusses Value Creation Initiatives, ESG, and Dementia Area Contributions Transcript Eisai Co., Ltd. (ESAIY) Discusses Value Creation Initiatives, ESG, and Dementia Area Contributions Transcript
globenewswire.com Eisai Presents New Data on the Continued and Expanding Benefit of LEQEMBI® (lecanemab-irmb) Maintenance Treatment in Early Alzheimer's Disease at the Clinical Trials on Alzheimer's Disease (CTAD) Conference 2025 Long-term LEQEMBI treatment suggests potential to delay disease progression from Mild Cognitive Impairment (MCI) to moderate Alzheimer's disease by up to 8.3 years in low-amyloid group who started…
prnewswire.com Eisai Presents New Data on the Continued and Expanding Benefit of LEQEMBI® (lecanemab-irmb) Maintenance Treatment in Early Alzheimer's Disease at the Clinical Trials on Alzheimer's Disease (CTAD) Conference 2025 TOKYO and CAMBRIDGE, Mass., Dec. 3, 2025 /PRNewswire/ -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge,…
prnewswire.com Eisai Presents New Data on Anti-Tau Antibody Etalanetug (E2814) at CTAD 2025 Etalanetug demonstrated reduction of eMTBR-tau243, a novel CSF and plasma biomarker that specifically reflects tau tangle pathology, in Phase I b /II study TOKYO , Dec. 1, 2025 /PRNewswire/ -- Eisai…
globenewswire.com Eisai Submits New Drug Application for Subcutaneous Formulation of “LEQEMBI®” for the Treatment of Early Alzheimer's Disease in Japan If approved, lecanemab would be the first and only anti-amyloid treatment in Japan to offer an at-home injection from the initiation of treatment for this progressive, relentless disease If approved,…
globenewswire.com Eisai Completes Rolling Submission to US FDA for LEQEMBI® IQLIK™ (lecanemab-irmb) Supplemental Biologics License Application as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer's Disease Under Fast Track Status LEQEMBI IQLIK, if approved for initiation dosing, would be the first and only anti-amyloid treatment to offer at-home injection from the start of therapy to help patients and care partners treat this…